Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of F-652 in acute-on-chronic liver failure
CTR20212657Phase 2Active
- Sponsor
- Evive Biotech
- Start
- Dec 2021
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of eflepedocokin alfa in acute-on-chronic liver failure (ACLF), sponsored by Evive Biotech. Started Dec 2021; status: active.
02
Drugs
eflepedocokin alfa
03
Conditions
acute-on-chronic liver failure (ACLF)
Beyond the preview
Go deeper on CTR20212657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212657.